Who Paid My Doc
Jorge Santana Bagur
Infectious Disease Manati, PR Medical Doctor
NPI 1063463586 CMS profile 139441
Manati Med Ctr Alejandro Otero Lopez, Urb Atenas, Manati, PR 00674
General payments
$180,226
Research payments
$3,238
Ownership & investment interest
$0
Research they led as principal investigator
$325,160
Through program year 2025, Jorge Santana Bagur of Manati, PR is reported in the CMS Open Payments database as having received $180,226 across 263 general payments and $3,238 in research payments paid to them. Separately, studies naming them as principal investigator received $325,160 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $3,313 | 10 | |
| 2024 | General | $15,919 | 20 | |
| 2023 | General | $16,899 | 21 | |
| 2022 | General | $21,153 | 25 | |
| 2022 | Research | $326 | 1 | |
| 2021 | General | $10,128 | 12 | |
| 2020 | General | $28,112 | 36 | |
| 2020 | Research | $1,502 | 16 | |
| 2019 | General | $84,702 | 139 | |
| 2019 | Research | $1,409 | 14 |
Beside peers
- Jorge Santana Bagur
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Jorge Santana Bagur were reported at $3,313. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Jorge Santana Bagur | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $84,702 | $190 | $60–$862 | $163 |
| 2020 | $28,112 | $124 | $32–$606 | $114 |
| 2021 | $10,128 | $148 | $38–$905 | $132 |
| 2022 | $21,153 | $166 | $50–$834 | $149 |
| 2023 | $16,899 | $171 | $57–$787 | $160 |
| 2024 | $15,919 | $176 | $52–$752 | $164 |
| 2025 | $3,313 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
294 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in Puerto Rico
Marisel Bosques Rosado
Infectious Disease · Hato Rey, PR
Francisco Alvarado
Infectious Disease · Caguas, PR
Jorge Bertran-Pasarell
Infectious Disease · Hato Rey, PR
Joel Munoz Coreano
Infectious Disease · Bayamon, PR
Vanessa Olivo Echavarry
Infectious Disease · San Juan, PR
Carlos Guzman Ortiz
Infectious Disease · Aibonito, PR
Related records
Infectious Disease in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.